Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate Brain
GlobeNewswire
RNAfix achieves up to 92% editing in the non-human primate brain after AAV-based gRNA deliveryRNAfix achieves >95% editing..
RNAfix achieves up to 92% editing in the non-human primate brain after AAV-based gRNA deliveryRNAfix achieves >95% editing..
· Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to..
Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month..